- Home
- STRM vs KPRX Comparison
STRM vs KPRX Comparison
Compare STRM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRM
- KPRX
- Stock Information
- Founded
- STRM 1989
- KPRX 1998
- Country
- STRM United States
- KPRX United States
- Employees
- STRM N/A
- KPRX N/A
- Industry
- STRM EDP Services
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STRM Technology
- KPRX Health Care
- Exchange
- STRM Nasdaq
- KPRX Nasdaq
- Market Cap
- STRM 9.3M
- KPRX 11.0M
- IPO Year
- STRM 1996
- KPRX N/A
- Fundamental
- Price
- STRM $3.15
- KPRX $3.37
- Analyst Decision
- STRM
- KPRX Strong Buy
- Analyst Count
- STRM 0
- KPRX 1
- Target Price
- STRM N/A
- KPRX $10.00
- AVG Volume (30 Days)
- STRM 32.2K
- KPRX 45.8K
- Earning Date
- STRM 12-11-2024
- KPRX 12-03-2024
- Dividend Yield
- STRM N/A
- KPRX N/A
- EPS Growth
- STRM N/A
- KPRX N/A
- EPS
- STRM N/A
- KPRX 1.69
- Revenue
- STRM $20,301,000.00
- KPRX $16,020,000.00
- Revenue This Year
- STRM N/A
- KPRX N/A
- Revenue Next Year
- STRM $4.04
- KPRX N/A
- P/E Ratio
- STRM N/A
- KPRX $2.01
- Revenue Growth
- STRM N/A
- KPRX N/A
- 52 Week Low
- STRM $1.85
- KPRX $3.00
- 52 Week High
- STRM $9.75
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- STRM 57.65
- KPRX 46.21
- Support Level
- STRM $2.82
- KPRX $3.20
- Resistance Level
- STRM $3.72
- KPRX $3.49
- Average True Range (ATR)
- STRM 0.36
- KPRX 0.19
- MACD
- STRM 0.12
- KPRX -0.03
- Stochastic Oscillator
- STRM 65.87
- KPRX 32.66
About STRM Streamline Health Solutions Inc.
Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.